⌘K
t
Tissue Regenix Group PLC announced the appointment of Jay LeCoque, aged 62, as Executive Chairman, effective 08 September 2025; Mr. LeCoque and closely associated persons currently hold no shares in the company. Concurrently, Jonathan Glenn resigned as Chairman and Trevor Phillips resigned as Non-Executive Director, both effective on the same date.
| Date | 8 Sept 2025 |
| Time | 07:00:10 |
| Category | Board changes |
| ID | 2934Y |
Tissue Regenix Group plc
('Tissue Regenix' or 'the Group')
Board Changes
Jay LeCoque appointed as Executive Chairman
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces the following changes to its Board of Directors.
Jay LeCoque will join the Board of Tissue Regenix as Executive Chairman, effective from today. Jay brings extensive experience from his role as Executive Chairman of Source BioScience Limited, Commercial Director of Bioquell PLC, and CEO of Celsis International PLC and Limited. He has over 25 years of senior management experience in the global business development of UK listed and privately held life sciences companies.
Jonathan Glenn, Chairman, and Trevor Phillips, Non-Executive Director, have both resigned from the Board, effective from today. The Company thanks both Jonathan and Trevor for their dedication and valuable contributions during their time on the Board.
Daniel Lee, CEO of Tissue Regenix, commented: "On behalf of the Board, I would like to thank Jonathan and Trevor for their commitment and support to the Company over the years. They have each made valued contributions to the Group and I wish them all the best in their future endeavours.
"We are pleased to appoint Jay LeCoque as Executive Chairman. His extensive knowledge and experience in the global healthcare and the clinical life sciences sector will contribute greatly to the business as we continue to grow and strengthen earnings to meet our long-term objectives."
Additional disclosures required under Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies
Jay Charles LeCoque, aged 62, has held the following directorships or partnerships in the past five years:
|
Current Directorships |
Previous Directorships (within the past five years) |
|
Cryobank Guarantor Limited |
Source Bioscience (Storage) Limited |
|
Fairfield Telepathology Limited |
Source Bioscience (Healthcare) Limited |
|
Source Bioscience (Cryobank) Limited |
Geneservice Limited |
|
Source Bioscience (Orchard Place) Limited |
Quinoderm Limited |
|
Kinetic Imaging Limited |
Select Storage Solutions (Scotland) Ltd |
|
Fairfield Imaging Limited |
Medical Solutions (Leeds) Limited |
|
Source Bioscience Scotland Limited |
|
|
Source Bioscience Uk Limited |
|
|
Select Pharma Laboratories Ltd |
|
|
Sourcebio International Limited |
|
|
Source Bioscience Limited |
|
|
LDPath Limited |
|
|
Source Genomics Limited |
|
|
Cambridge Clinical Laboratories Ltd |
|
|
Rivage Ventures LLC |
|
Mr LeCoque and persons closely associated (as defined under MAR) with Mr LeCoque do not currently hold any shares in the Company.
Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.
For more information:
|
Tissue Regenix Group plc |
|
|
Daniel Lee, Chief Executive Officer Brandon Largent, Interim Chief Financial Officer |
via Walbrook PR |
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
Geoff Nash/Giles Balleny/Edward Whiley |
Tel: +44 (0) 20 7466 5000 |
|
Nigel Birks - Life Science Specialist Sales |
|
|
Harriet Ward - ECM |
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
Alice Woodings |
TissueRegenix@walbrookpr.com |
|
|
|
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.